TradingKey

TradingKey - Anthropic  is holding early discussions with top Wall Street banks about leading an initial public offering that could come as soon as October, according to people familiar with the matter.

TradingKey - Impacted by the ongoing geopolitical conflict, Asia-Pacific stock markets generally opened under pressure on Thursday amid rising external uncertainty and retreating market risk appetite. Major indices fell across the board, with the South Korean market recording particularly significant losses.

TradingKey - As U.S.-Iran ceasefire negotiations reached a stalemate, market risk aversion intensified rapidly. International oil prices surged over 4% at one point, while risk assets including U.S. equities, Treasuries, gold, and Bitcoin came under simultaneous pressure.

• Analyst earnings estimates and price targets were reduced. • Institutional investors significantly reduced their stakes. • Global regulatory uncertainties pose operational risks.

• Analysts raised Valero Energy's price targets and ratings. • Strengthening refining margins and geopolitical tensions benefit Valero. • Valero demonstrates operational resilience despite refinery incident.

• NHTSA probe escalates into Tesla's FSD technology. • California clarifies robotaxi is not fully autonomous. • Analysts lower Tesla's vehicle delivery outlooks.

• Banco Santander's stock price declined due to global uncertainty and geopolitical concerns. • Mixed analyst ratings and technical indicators suggest potential short-term weakness. • Share buybacks and long-term growth plans aim to enhance shareholder value.

• Equinor begins drilling at Brazil's Raia project, boosting future production. • Upward earnings revisions and analyst price target increases support Equinor. • Geopolitical tensions and LNG supply disruptions benefit Equinor's operations.

• Stifel reiterated a Buy rating with a $90.00 price target on Boston Scientific. • Analysts maintain positive ratings with price targets ranging from $92 to $120. • Acquisition of Penumbra for $14.5 billion is expected to boost cardiovascular portfolio.

• Copper prices fell due to geopolitical tensions and high inventories. • Analysts are cautious on Southern Copper's valuation and production outlook. • Insider selling and technical indicators suggest negative sentiment.

• ConocoPhillips shares rose due to higher global oil prices. • Geopolitical tensions increased supply disruption fears in the Middle East. • Analysts maintain a "Buy" rating with an average price target of $126.04.

• Arm launched its AI data center CPU, Arm AGI. • Meta Platforms is a lead co-developer and primary customer. • Analysts upgraded ARM, with price targets raised significantly.

• Alphabet shares declined due to macroeconomic and regulatory factors. • Legal setbacks and global regulatory scrutiny impacted investor confidence. • Concerns persist over AI investment costs and advertising channel performance.

• Macroeconomic pressures and industry competition impacted NVIDIA. • Google's AI algorithm and AMD's potential deal add competitive pressure. • Renewed lawsuit and regulatory scrutiny create company-specific concerns.

• Eaton's 2026 guidance, below consensus, impacts share price. • Positive developments overshadowed by cautious earnings outlook. • Mixed institutional investor activity and neutral technical signals.

• Trane Technologies forecasts a challenging Q1 2026 due to inventory normalization. • Weak residential HVAC revenue and North American market softness are concerns. • Insider selling and institutional investor trimming contributed to stock decline.

• Amphenol's share price declined due to cautious guidance and executive sales. • Analyst sentiment shifted, with some downgrades and concerns over AI market share. • Insider selling by CEO and institutional position reductions added selling pressure.

• Quanta Services exceeded Q4 2025 earnings and revenue expectations. • Company projects strong FY2026 revenue and EPS above estimates. • Stock may be trading at a premium valuation despite positive outlook.

• Sanofi stock rose due to positive drug pipeline and regulatory news. • Dupixent approved in Japan for bullous pemphigoid, expanding market reach. • FDA granted Breakthrough Therapy designation for venglustat for Gaucher disease.

• Sherwin-Williams stock shows positive movement amid analyst support. • Company reported stronger than expected Q4 2025 earnings. • Facility expansion signals confidence in future market growth.